In patients with FD, how do you use genetic testing and results of enzyme activity levels of alpha-galactosidase A (a-Gal A) to determine whether oral chaperone therapy with migalastat vs. IV ERT is best suited for an individual patient?

In patients with FD, how do you use genetic testing and results of enzyme activity levels of alpha-galactosidase A (a-Gal A) to determine whether oral chaperone therapy with migalastat vs. IV ERT is best suited for an individual patient?

In patients with FD, how do use genetic testing and results of enzyme activity levels of alpha-galactosidase A (a-Gal A) to determine whether oral chaperone therapy with migalastat vs. IV ERT is best suited for an individual patient?


Created by

CMEducation Resources IQ&A Fabry Disease Diagnostic Intelligence Zone

Presenter

Robert Hopkin

Robert Hopkin

Associate Professor of Clinical Pediatrics
Cincinnati Children's Hospital Medical Center
Co-Director, 22Q-VCFS Center
University of Cincinnati College of Medicine
Cincinnati, OH